Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy

Nobuo Shinohara, Wataru Obara, Katsunori Tatsugami, Sei Naito, Tomomi Kamba, Masayuki Takahashi, Sachiyo Murai, Takashige Abe, Koji Oba, Seiji Naito

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A multicenter cooperative study was conducted to clarify the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy and the clinical usefulness of the Japanese metastatic renal cancer (JMRC) prognostic classification. Of 389 consecutive patients for whom treatment was started between 2008 and 2010 at 23 hospitals in Japan, 357 patients who received vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) or cytokine as initial systemic therapy were the subject of the present study. Patients were classified into three prognostic groups according to the JMRC prognostic classification. The endpoints were progression-free survival (PFS) and overall survival (OS) after the start of the initial treatment. The median PFS and OS for the entire cohort of 357 patients were 9.1 and 27.2 months, respectively. VEGFR-TKI were selected for patients with multiple organ metastases, those with liver metastasis, and those with bone metastasis. The median PFS and OS were 11.0 and 23.2 months and 5.4 and 38.2 months in the VEGFR-TKI group and the cytokines group, respectively. The JMRC prognostic classification was useful as a prognostic model for PFS and OS (c-indexes: 0.613 and 0.630 in patients who initially received VEGFR-TKI and 0.647 and 0.642 in patients who received cytokines, respectively). The present study showed for the first time the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy. The JMRC prognostic classification may be clinically useful as a prognostic model.

Original languageEnglish
Pages (from-to)618-626
Number of pages9
JournalCancer Science
Volume106
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Molecular Targeted Therapy
Renal Cell Carcinoma
Vascular Endothelial Growth Factor Receptor
Kidney Neoplasms
Protein-Tyrosine Kinases
Disease-Free Survival
Survival
Cytokines
Neoplasm Metastasis
Multicenter Studies
Japan
Therapeutics
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. / Shinohara, Nobuo; Obara, Wataru; Tatsugami, Katsunori; Naito, Sei; Kamba, Tomomi; Takahashi, Masayuki; Murai, Sachiyo; Abe, Takashige; Oba, Koji; Naito, Seiji.

In: Cancer Science, Vol. 106, No. 5, 01.05.2015, p. 618-626.

Research output: Contribution to journalArticle

Shinohara, N, Obara, W, Tatsugami, K, Naito, S, Kamba, T, Takahashi, M, Murai, S, Abe, T, Oba, K & Naito, S 2015, 'Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy', Cancer Science, vol. 106, no. 5, pp. 618-626. https://doi.org/10.1111/cas.12646
Shinohara, Nobuo ; Obara, Wataru ; Tatsugami, Katsunori ; Naito, Sei ; Kamba, Tomomi ; Takahashi, Masayuki ; Murai, Sachiyo ; Abe, Takashige ; Oba, Koji ; Naito, Seiji. / Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. In: Cancer Science. 2015 ; Vol. 106, No. 5. pp. 618-626.
@article{d69578ea136b414b93afdfebe22e4f33,
title = "Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy",
abstract = "A multicenter cooperative study was conducted to clarify the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy and the clinical usefulness of the Japanese metastatic renal cancer (JMRC) prognostic classification. Of 389 consecutive patients for whom treatment was started between 2008 and 2010 at 23 hospitals in Japan, 357 patients who received vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) or cytokine as initial systemic therapy were the subject of the present study. Patients were classified into three prognostic groups according to the JMRC prognostic classification. The endpoints were progression-free survival (PFS) and overall survival (OS) after the start of the initial treatment. The median PFS and OS for the entire cohort of 357 patients were 9.1 and 27.2 months, respectively. VEGFR-TKI were selected for patients with multiple organ metastases, those with liver metastasis, and those with bone metastasis. The median PFS and OS were 11.0 and 23.2 months and 5.4 and 38.2 months in the VEGFR-TKI group and the cytokines group, respectively. The JMRC prognostic classification was useful as a prognostic model for PFS and OS (c-indexes: 0.613 and 0.630 in patients who initially received VEGFR-TKI and 0.647 and 0.642 in patients who received cytokines, respectively). The present study showed for the first time the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy. The JMRC prognostic classification may be clinically useful as a prognostic model.",
author = "Nobuo Shinohara and Wataru Obara and Katsunori Tatsugami and Sei Naito and Tomomi Kamba and Masayuki Takahashi and Sachiyo Murai and Takashige Abe and Koji Oba and Seiji Naito",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/cas.12646",
language = "English",
volume = "106",
pages = "618--626",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy

AU - Shinohara, Nobuo

AU - Obara, Wataru

AU - Tatsugami, Katsunori

AU - Naito, Sei

AU - Kamba, Tomomi

AU - Takahashi, Masayuki

AU - Murai, Sachiyo

AU - Abe, Takashige

AU - Oba, Koji

AU - Naito, Seiji

PY - 2015/5/1

Y1 - 2015/5/1

N2 - A multicenter cooperative study was conducted to clarify the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy and the clinical usefulness of the Japanese metastatic renal cancer (JMRC) prognostic classification. Of 389 consecutive patients for whom treatment was started between 2008 and 2010 at 23 hospitals in Japan, 357 patients who received vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) or cytokine as initial systemic therapy were the subject of the present study. Patients were classified into three prognostic groups according to the JMRC prognostic classification. The endpoints were progression-free survival (PFS) and overall survival (OS) after the start of the initial treatment. The median PFS and OS for the entire cohort of 357 patients were 9.1 and 27.2 months, respectively. VEGFR-TKI were selected for patients with multiple organ metastases, those with liver metastasis, and those with bone metastasis. The median PFS and OS were 11.0 and 23.2 months and 5.4 and 38.2 months in the VEGFR-TKI group and the cytokines group, respectively. The JMRC prognostic classification was useful as a prognostic model for PFS and OS (c-indexes: 0.613 and 0.630 in patients who initially received VEGFR-TKI and 0.647 and 0.642 in patients who received cytokines, respectively). The present study showed for the first time the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy. The JMRC prognostic classification may be clinically useful as a prognostic model.

AB - A multicenter cooperative study was conducted to clarify the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy and the clinical usefulness of the Japanese metastatic renal cancer (JMRC) prognostic classification. Of 389 consecutive patients for whom treatment was started between 2008 and 2010 at 23 hospitals in Japan, 357 patients who received vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) or cytokine as initial systemic therapy were the subject of the present study. Patients were classified into three prognostic groups according to the JMRC prognostic classification. The endpoints were progression-free survival (PFS) and overall survival (OS) after the start of the initial treatment. The median PFS and OS for the entire cohort of 357 patients were 9.1 and 27.2 months, respectively. VEGFR-TKI were selected for patients with multiple organ metastases, those with liver metastasis, and those with bone metastasis. The median PFS and OS were 11.0 and 23.2 months and 5.4 and 38.2 months in the VEGFR-TKI group and the cytokines group, respectively. The JMRC prognostic classification was useful as a prognostic model for PFS and OS (c-indexes: 0.613 and 0.630 in patients who initially received VEGFR-TKI and 0.647 and 0.642 in patients who received cytokines, respectively). The present study showed for the first time the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy. The JMRC prognostic classification may be clinically useful as a prognostic model.

UR - http://www.scopus.com/inward/record.url?scp=84929709476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929709476&partnerID=8YFLogxK

U2 - 10.1111/cas.12646

DO - 10.1111/cas.12646

M3 - Article

C2 - 25711777

AN - SCOPUS:84929709476

VL - 106

SP - 618

EP - 626

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -